$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

2022 Q1 Form 10-Q Financial Statement

#000147793222003286 Filed on May 13, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021 Q1
Revenue $15.00K $67.75K $0.00
YoY Change 287.14% -100.0%
Cost Of Revenue $6.791K $39.45K $0.00
YoY Change 393.13% -100.0%
Gross Profit $8.209K $28.30K $0.00
YoY Change 197.89% -100.0%
Gross Profit Margin 54.73% 41.77%
Selling, General & Admin $1.130M $1.428M $280.9K
YoY Change 302.27% 352.2% -18.85%
% of Gross Profit 13766.07% 5045.97%
Research & Development $10.00K $50.00K
YoY Change
% of Gross Profit 121.82% 176.68%
Depreciation & Amortization $23.02K $23.02K $23.02K
YoY Change 0.0% 37.27% 37.27%
% of Gross Profit 280.42% 81.34%
Operating Expenses $1.163M $1.501M $303.9K
YoY Change 282.67% 351.36% -16.26%
Operating Profit -$1.155M -$1.473M -$303.9K
YoY Change 279.97% 355.87% -9.28%
Interest Expense $0.00 -$2.403M $28.14M
YoY Change -100.0% -93.73% 590.12%
% of Operating Profit
Other Income/Expense, Net $0.00 $28.14M
YoY Change -100.0%
Pretax Income -$1.155M -$3.875M $27.84M
YoY Change -104.15% -89.97% 643.79%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$1.155M -$3.875M $27.84M
YoY Change -104.15% -89.97% 643.79%
Net Earnings / Revenue -7699.13% -5720.25%
Basic Earnings Per Share -$0.18 $12.22
Diluted Earnings Per Share -$0.18 -$1.113M $11.18
COMMON SHARES
Basic Shares Outstanding 6.454M shares 2.452M shares 2.277M shares
Diluted Shares Outstanding 1.245B shares

Balance Sheet

Concept 2022 Q1 2021 Q4 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.147M $10.72M $275.1K
YoY Change 3224.6% 10841.61% 617.79%
Cash & Equivalents $9.147M $10.72M $275.1K
Short-Term Investments
Other Short-Term Assets $64.96K
YoY Change
Inventory $14.15K $10.87K
Prepaid Expenses
Receivables $0.00 $2.490K
Other Receivables $0.00 $0.00
Total Short-Term Assets $9.226M $10.74M $275.1K
YoY Change 3253.36% 10855.01% 455.48%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.281K $3.281K
YoY Change
Total Long-Term Assets $507.9K $531.0K $596.8K
YoY Change -14.88% -14.33% 42.16%
TOTAL ASSETS
Total Short-Term Assets $9.226M $10.74M $275.1K
Total Long-Term Assets $507.9K $531.0K $596.8K
Total Assets $9.734M $11.27M $871.9K
YoY Change 1016.44% 1469.88% 85.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $335.7K $761.9K $356.0K
YoY Change -5.71% 117.12% -7.91%
Accrued Expenses $29.92K $24.39K $67.76K
YoY Change -55.84% -84.74% -50.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $327.2K
YoY Change -100.0% -100.0% -68.27%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $379.8K $1.050M $3.314M
YoY Change -88.54% -97.41% -9.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $379.8K $1.050M $3.314M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $379.8K $1.050M $3.314M
YoY Change -88.54% -97.41% -9.23%
SHAREHOLDERS EQUITY
Retained Earnings -$44.82M -$43.67M
YoY Change -29.44%
Common Stock $6.521K $6.339K
YoY Change 312.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.354M $10.22M -$2.443M
YoY Change
Total Liabilities & Shareholders Equity $9.734M $11.27M $871.9K
YoY Change 1016.44% 1469.88% 85.78%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021 Q1
OPERATING ACTIVITIES
Net Income -$1.155M -$3.875M $27.84M
YoY Change -104.15% -89.97% 643.79%
Depreciation, Depletion And Amortization $23.02K $23.02K $23.02K
YoY Change 0.0% 37.27% 37.27%
Cash From Operating Activities -$1.577M -$1.161M -$441.5K
YoY Change 257.15% -2138.14% 126.05%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities $0.00 $200.0K $0.00
YoY Change -180.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $0.00 9.307M $618.6K
YoY Change -100.0% 3588.68% 326.65%
NET CHANGE
Cash From Operating Activities -$1.577M -1.161M -$441.5K
Cash From Investing Activities $0.00 200.0K $0.00
Cash From Financing Activities $0.00 9.307M $618.6K
Net Change In Cash -$1.577M 8.346M $177.1K
YoY Change -990.29% 13974.11% -451.99%
FREE CASH FLOW
Cash From Operating Activities -$1.577M -$1.161M -$441.5K
Capital Expenditures $0.00
Free Cash Flow -$1.161M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9506392 shares
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3281 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3281 USD
CY2022Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6520690 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6338872 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6520682 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6338864 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
6521 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
6339 USD
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
54170393 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
53879215 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44822683 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43667814 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
9354231 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10217740 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9734026 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11268181 USD
CY2022Q1 us-gaap Revenues
Revenues
15000 USD
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
6791 USD
CY2022Q1 us-gaap Gross Profit
GrossProfit
8209 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10000 USD
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1130057 USD
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23021 USD
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
1163078 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1154869 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
0 USD
CY2022Q1 celz Change In Fair Value Of Derivatives Liabilities
ChangeInFairValueOfDerivativesLiabilities
0 USD
CY2021Q1 celz Change In Fair Value Of Derivatives Liabilities
ChangeInFairValueOfDerivativesLiabilities
28476039 USD
CY2022Q1 us-gaap Interest Income Expense After Provision For Loan Loss
InterestIncomeExpenseAfterProvisionForLoanLoss
0 USD
CY2021Q1 us-gaap Interest Income Expense After Provision For Loan Loss
InterestIncomeExpenseAfterProvisionForLoanLoss
0 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
12.22
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
11.18
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6454015 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2277121 shares
CY2022Q1 celz Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
6454015 shares
CY2021Q1 celz Weighted Average Number Of Shares Outstanding Diluted
WeightedAverageNumberOfSharesOutstandingDiluted
2489059 shares
CY2022Q1 us-gaap Profit Loss
ProfitLoss
1154869 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-27836019 USD
CY2022Q1 celz Stock Based Compensations
StockBasedCompensations
41360 USD
CY2021Q1 celz Stock Based Compensations
StockBasedCompensations
0 USD
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23021 USD
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23021 USD
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
231232 USD
CY2022Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 USD
CY2021Q1 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-28476039 USD
CY2022Q1 celz Ncrease In Principal And Accrued Interest Balances Due To Penalty Provision
NcreaseInPrincipalAndAccruedInterestBalancesDueToPenaltyProvision
0 USD
CY2021Q1 celz Ncrease In Principal And Accrued Interest Balances Due To Penalty Provision
NcreaseInPrincipalAndAccruedInterestBalancesDueToPenaltyProvision
-93821 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2022Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
64960 USD
CY2021Q1 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
0 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-426181 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5102 USD
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5535 USD
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
9026 USD
CY2022Q1 us-gaap Increase Decrease In Payables To Customers
IncreaseDecreaseInPayablesToCustomers
0 USD
CY2021Q1 us-gaap Increase Decrease In Payables To Customers
IncreaseDecreaseInPayablesToCustomers
-163700 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1576893 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-441518 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2021Q1 celz Proceeds From Sales Of Preferred Stock Amount
ProceedsFromSalesOfPreferredStockAmount
462000 USD
CY2021Q1 celz Common Stock Issued For Related Party Management Liabilities Amount
CommonStockIssuedForRelatedPartyManagementLiabilitiesAmount
50000 USD
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
887563 USD
CY2021Q1 us-gaap Derivative Gain On Derivative
DerivativeGainOnDerivative
8124855 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
27836019 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-2442573 USD
CY2022Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
CY2021Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
134640 USD
CY2022Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 USD
CY2021Q1 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
462000 USD
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
CY2021Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
22000 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
618640 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1576893 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
177122 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10723870 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98012 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9146977 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
275134 USD
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
9186 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2021Q1 celz Conversion Of Notes Payable Accrued Interest And Derivative Liabilities Into Common Stock
ConversionOfNotesPayableAccruedInterestAndDerivativeLiabilitiesIntoCommonStock
9012418 USD
CY2021Q1 celz Conversion Of Management Fees And Patent Liability Into Common Stock
ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock
50000 USD
CY2021Q1 celz Discounts On Convertible Notes Payable Due To Derivative Liabilities
DiscountsOnConvertibleNotesPayableDueToDerivativeLiabilities
134640 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
10217740 USD
CY2022Q1 celz Common Stock Issued For Related Party Patent Liabilities Amount
CommonStockIssuedForRelatedPartyPatentLiabilitiesAmount
250000 USD
CY2022Q1 celz Stock Based Compensation
StockBasedCompensation
41360 USD
CY2022Q1 celz Net Loss
NetLoss
-1154869 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
9354231 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-39803010 USD
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Use of Estimates</strong></em> – The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q1 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
250000 USD
CY2021Q1 celz Weighted Average Common Shares Outstanding Used In Calculating Basic Earnings Per Share
WeightedAverageCommonSharesOutstandingUsedInCalculatingBasicEarningsPerShare
1138560486 shares
CY2021Q1 celz Effect Of Series B And C Preferred Stock Share
EffectOfSeriesBAndCPreferredStockShare
12000000 shares
CY2021Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
64785779 shares
CY2021Q1 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
28949143 shares
CY2021Q1 celz Incremental Common Shares Attributable To Dilutive Effect Of Convertible Related Party Management Fee And Patent Liabilities
IncrementalCommonSharesAttributableToDilutiveEffectOfConvertibleRelatedPartyManagementFeeAndPatentLiabilities
234194 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1244529602 shares
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
27836019 USD
CY2021Q1 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
53718 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
27889737 USD
CY2016Q1 celz No Of Share Exchange
NoOfShareExchange
431111 shares
CY2016Q1 celz Restricted Common Stock
RestrictedCommonStock
100000 USD
CY2019Q4 celz Cash Payment In Intial Payment
CashPaymentInIntialPayment
50000 USD
CY2019Q4 celz Common Stock Issue Share
CommonStockIssueShare
6667 shares
CY2021Q1 celz Company Paid
CompanyPaid
50000 USD
CY2021Q1 celz Obligation Of The Initial Payment
ObligationOfTheInitialPayment
300000 USD
CY2021Q1 celz Common Stock Issue Share
CommonStockIssueShare
133 shares
CY2020Q3 celz Company Paid
CompanyPaid
40000 USD
CY2020Q3 celz Obligation Of The Initial Payment
ObligationOfTheInitialPayment
300000 USD
CY2020Q3 celz Common Stock Issue Share
CommonStockIssueShare
84656 shares
CY2021Q1 celz Company Paid
CompanyPaid
50000 USD
CY2021Q1 celz Common Stock Issue Share
CommonStockIssueShare
89286 shares
CY2021Q1 celz Obligation Of The Initial Payment
ObligationOfTheInitialPayment
300000 USD
CY2020Q4 celz License Fees
LicenseFees
250000 USD
CY2020Q4 celz License Agreement Description
LicenseAgreementDescription
the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
CY2022Q1 celz Continuing Royalty Description
ContinuingRoyaltyDescription
Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™
CY2021Q4 celz Licensing Agreements Beginning Balance
LicensingAgreementsBeginningBalance
760000 USD
CY2021Q4 celz Accumulated Amortization Beginning Balance
AccumulatedAmortizationBeginningBalance
-232321 USD
CY2022Q1 celz Accumulated Amortization Addition Of New Assets
AccumulatedAmortizationAdditionOfNewAssets
0 USD
CY2022Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
0 USD
CY2022Q1 celz Accumulated Amortization
AccumulatedAmortization
-23021 USD
CY2022Q1 celz Licensing Agreementsendingbalance
LicensingAgreementsendingbalance
760000 USD
CY2022Q1 celz Accumulated Amortization Ending Balance
AccumulatedAmortizationEndingBalance
-255342 USD
CY2021Q2 celz Proceeds From Chairman
ProceedsFromChairman
50000 USD
CY2021Q2 celz Proceeds From Director
ProceedsFromDirector
150000 USD
CY2021Q3 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.05 pure
CY2021Q1 us-gaap Interest Expense Other
InterestExpenseOther
231232 USD
CY2021Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
335568 USD
CY2021Q1 celz Debt Conversion Shares Issued
DebtConversionSharesIssued
629404 shares
CY2021Q1 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
887560 USD
CY2021Q1 celz Debt Conversion Converrted Instrument Shares Issued
DebtConversionConverrtedInstrumentSharesIssued
20111 shares
CY2021Q1 celz Common Stock Issued For Cashless Warrant Exercise Shares
CommonStockIssuedForCashlessWarrantExerciseShares
23167 shares
CY2021Q1 celz Initial Derivative Liabilities
InitialDerivativeLiabilities
817791 USD
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P1Y
CY2021Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
683151 USD
CY2021Q1 celz Gain Loss Related To Change In Fair Market Value Of Derivative Liabilities
GainLossRelatedToChangeInFairMarketValueOfDerivativeLiabilities
29159190 USD
CY2021Q1 celz Share Price On Reveluation
SharePriceOnReveluation
16.60
CY2021Q1 celz Derivative Liabilities Fair Value
DerivativeLiabilitiesFairValue
8124855 USD
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0081 pure
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.9295 pure
CY2022Q1 us-gaap Share Price
SharePrice
1.69

Files In Submission

Name View Source Status
0001477932-22-003286-index-headers.html Edgar Link pending
0001477932-22-003286-index.html Edgar Link pending
0001477932-22-003286.txt Edgar Link pending
0001477932-22-003286-xbrl.zip Edgar Link pending
celz-20220331.xsd Edgar Link pending
celz-20220331_cal.xml Edgar Link unprocessable
celz-20220331_def.xml Edgar Link unprocessable
celz-20220331_lab.xml Edgar Link unprocessable
celz-20220331_pre.xml Edgar Link unprocessable
celz_10q.htm Edgar Link pending
celz_10qimg1.jpg Edgar Link pending
celz_10q_htm.xml Edgar Link completed
celz_ex311.htm Edgar Link pending
celz_ex312.htm Edgar Link pending
celz_ex321.htm Edgar Link pending
celz_ex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending